Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REEF-2
NCT04129554Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2019
- Primary completion
- Jul 2021
- Modality
- Conjugated siRNA, Peptide-Drug Conjugates, Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of tomligisiran, bersacapavir in Chronic Hepatitis B (CHB), sponsored by Janssen Pharmaceutical. Started Nov 2019; status: completed.
02
Drugs
tomligisiranbersacapavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04129554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04129554.